In particular, the phase 3 randomized NeoADAURA trial, is evaluating the efficacy and safety of neoadjuvant osimertinib, as monotherapy or in combination with chemotherapy, vs. chemotherapy with placebo in patients with resectable stage II–IIIB (N2) EGFR-positive NSCLC [53]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.